Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
View Patent ↗Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula I:
wherein
R 1 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl;
R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, substituted alkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl,
R 3 is selected from the group consisting of hydrogen, alkyl, substituted alkyl cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
R 5 is —(CH) 2 ) x —Ar—R 5′ where R 5 is selected from the group consisting of —O—Z—NR 8 R 8′ and —O—Z—R 12 wherein R 8 and R 8′ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, and where R 8 and R 8′ are joined to form a heterocycle or a substituted heterocycle, R 12 is selected from the group consisting of heterocycle and substituted heterocycle, and Z is selected from the group consisting of —C(O)— and —SO 2 —,
Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl,
x is an integer of from 1 to 4;
Q is —C(X)NR 7 — wherein R 7 is selected from the group consisting of hydrogen and alkyl; and X is selected from the group consisting of oxygen and sulfur;
and pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula IA:
wherein
R 1 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl;
R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, substituted alkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
R 3 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
R 5 is —(CH 2 ) x —Ar—R 5′ and R 5′ is selected from the group consisting of —O—Z—NR 8 R 8′ and —O—Z—R 12 wherein R 8 and R 8′ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, and where R 8 and R 8 are joined to form a heterocycle or a substituted heterocycle, R 12 is selected from the group consisting of heterocycle and substituted heterocycle, and Z is selected from the group consisting of —C(O)— and —SO 2 —,
Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl,
x is an integer of from 1 to 4;
R 6 is selected from the group consisting of amino, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, —O-(N-succinimidyl), —NH-adamantyl, —O-cholest-5-en-3-β-yl, —NHOY where Y is hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl, —NH(CH 2 ) p COOY where p is an integer of from 1 to 8 and Y is as defined above, —OCH 2 NR 9 R 10 where R 9 is selected from the group consisting of —C(O)-aryl and —C(O)-substituted aryl and R 10 is selected from the group consisting of hydrogen and —CH 2 COOR 11 where R 11 is alkyl, and —NHSO 2 Z′ where Z′ is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;
Q is —C(X)NR 7 — wherein R 7 is selected from the group consisting of hydrogen and alkyl; and X is selected from the group consisting of oxygen and sulfur;
and pharmaceutically acceptable salts thereof.
3. A pharmaceutical composition according to claims 1 or 2 wherein R 1 is selected from the group consisting of methyl, isopropyl, n-butyl, benzyl, phenethyl, phenyl,4-methylphenyl, 4-t-butylphenyl, 2,4,6-trimethylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlolorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 3-chloro-4-fluorophenyl, 4-bromophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 4-t-butoxyphenyl, 4-(3′-dimethylamino-n-propoxy)-phenyl, 2-carboxyphenyl, 2-(methoxy-carbonyl)phenyl, 4-(H 2 NC(O)—)phenyl, 4-(H 2 NC(S)—)phenyl, 4-cyanophenyl, 4-trifluoro-methylphenyl, 4-trifluoromethoxyphenyl, 3,5-di-(trifluoromethyl)-phenyl, 4-nitrophenyl, 4-aminophenyl, 4-(CH 3 C(O)NH—)phenyl, 4-(PhNHC(O)NH—)phenyl, 4-amidinophenyl, 4-methylamidinophenyl, 4-(CH 3 SC(═NH)—)phenyl, 4-chloro-3-(H 2 NS(O) 2 —)phenyl, 1-naphthyl, 2-naphthyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, quinolin-8-yl, 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-yl, morpholin-4-yl, 2-thienyl, 5-chloro-2-thienyl, 2,5-dichloro-4-thienyl, 1-N-methylimidazol-4-yl, 1-N-methylpyrazol-3-yl, 1-N-methylpyrazol-4-yl, 1-N-butylpyrazol-4-yl, 1-N-methyl-3-methyl-5-chloropyrazol-4-yl, 1-N-methyl-5-methyl-3-chloropyrazol-4-yl, 2-thiazolyl and 5-methyl-1,3,4-thiadiazol-2-yl.
4. A pharmaceutical composition according to claims 1 or 2 wherein R 2 is selected from the group consisting of hydrogen, methyl, phenyl, benzyl, —(CH 2 ) 2 -2-thienyl, and —(CH 2 ) 2 -φ.
5. A pharmaceutical composition according to claims 1 or 2 wherein R 3 is selected from the group consisting of methyl, phenyl, benzyl, diphenylmethyl, —CH 2 CH 2 —COOH, —CH 2 —COOH, 2-amidoethyl, iso-butyl, t-butyl, —CH 2 O-benzyl and hydroxymethyl.
6. A pharmaceutical composition according to claims 1 or 2 wherein Q is —C(O)NH— or —C(S)NH—.
7. A pharmaceutical composition according to claims 1 or 2 wherein Ar is aryl or substituted aryl.
8. A pharmaceutical composition according to claim 7 wherein Ar is phenyl or substituted phenyl and x is 1.
9. A pharmaceutical composition according to claims 1 or 2 wherein R 5 is selected from the group consisting of
3-[(CH 3 ) 2 NC(O)O—]benzyl,
4-[(CH 3 ) 2 NC(O)O—]benzyl,
4-[(CH 3 ) 2 NS(O) 2 O—]benzyl,
4-[(piperidin-1′-yl)C(O)O—]benzyl,
4-[(piperidin-4′-yl)C(O)O—]benzyl,
4-[(1′-methylpiperidin-4′-yl)C(O)O—]benzyl,
4-[(4′-hydroxypiperidin-1′-yl)C(O)O—]benzyl,
4-[(4′-formyloxypiperidin-1′-yl)C(O)O—]benzyl,
4-[(4′-ethoxycarbonylpiperidin-1′-yl)C(O)O—]benzyl,
4-[(4′-carboxylpiperidin-1′-yl)C(O)O—]benzyl,
4-[(3′-hydroxymethylpiperidin-1′-yl)C(O)O—]benzyl,
4-[(4′-hydroxymethylpiperidin-1′-yl)C(O)O—]benzyl,
4-[(4′-phenyl-1′-Boc-piperidin-4′-yl)—C(O)O—]benzyl,
4-[(4′-piperidon-1′-yl ethylene ketal)C(O)O—]benzyl,
4-[(piperazin-4′-yl)—C(O)O—]benzyl,
4-[(1′-Boc-piperazin-4′-yI)—C(O)O—]benzyl,
4-[(4′-methylpiperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-methylhomopiperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-(2-hydroxyethyl)piperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-phenylpiperazin-1′-yI)C(O)O—]benzyl,
4-[(4′-(pyridin-2-yl)piperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-(4-trifluoromethylpyridin-2-yl)piperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-(pyrimidin-2-yl)piperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-acetylpiperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-phenylC(O)—)piperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-pyridin-4-ylC(O)—)piperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-(phenylNHC(O)—)piperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-(phenylNHC(S)—)piperazin-1′-yl)C(O)O—]benzyl,
4-[(4′-methanesulfonylpiperazin-1′-yl-C(O)O—)benzyl,
4-[(4′-trifluoromethanesulfonylpiperazin-1′-yl-C(O)O—)benzyl,
4-((morpholin-4′-yl)C(O)O—]benzyl,
3-nitro-4-[(morpholin-4′-yl)—C(O)O—]benzyl,
4-[(thiomorpholin-4′-yl)C(O)O—]benzyl,
4-[(thiomorpholin-4′-yl sulfone)—C(O)O—]benzyl,
4-[(pyrrolidin-1′-yl)C(O)O—]benzyl,
4-[(2′-methylpyrrolidin-1′-yl)C(O)O—]benzyl,
4-[(2′-(methoxycarbonyl)pyrrolidin-1′-yl)C(O)O—]benzyl,
4-[(2′-(hydroxymethyl)pyrrolidin-1′-yl)C(O)O—]benzyl,
4-[(2′-(N,N-dimethylamino)ethyl)(CH 3 )NC(O)O—]benzyl,
4-[(2′-(N-methyl-N-toluene-4-sulfonylamino)ethyl)(CH 3 )N—C(O)O—]benzyl,
4-[(2′-(morpholin-4′-yl)ethyl)(CH 3 )NC(O)O—]benzyl,
4-[(2′-(hydroxy)ethyl)(CH 3 )NC(O)O—]benzyl,
4-(bis(2′-(hydroxy)ethyl)NC(O)O—]benzyl,
4-[(2′-(formyloxy)ethyl)(CH 3 )NC(O)O—]benzyl,
4-[(CH 3 OC(O)CH 2 )HNC(O)O—]benzyl,
4-[2′-(phenylNHC(O)O—)ethyl-]HNC(O)O—]benzyl,
3-chloro-4-[(CH 3 ) 2 NC(O)O—]benzyl,
3-chloro-4-[(4′-methylpiperazin-1′-yl)C(O)O—]benzyl,
3-chloro-4-[(4′-(pyridin-2-yl)piperazin-1′-yl)C(O)O—]benzyl,
3-chloro-4-[(thiomorpholin-4′-yl)C(O)O—]benzyl, and
3-fluoro-4-[(CH 3 ) 2 NC(O)O—]benzyl.
10. A pharmaceutical composition according to claim 2 wherein R 6 is selected from the group consisting of 2,4-dioxo-tetrahydrofuran-3-yl (3,4-enol), methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, cyclopentoxy, cyclopropylmethoxy, neopentoxy, 2-α-isopropyl-4-β-methylcyclohexoxy, 2-β-isopropyl-4-β-methylcyclohexoxy, 2-methoxyphenoxy, 2-(morpholin-4-yl)ethoxy, —O(CH 2 CH 2 O) 2 CH 3 , 2-(phenoxy)ethoxy, —OCH 2 C(CH 3 ) 2 NHBoc, —NH 2 , benzyloxy, —NHCH 2 COOH, —NHCH 2 CH 2 COOH, —NH-adamantyl, —NHSO 2 -p-CH 3 -φ, —NHCH 2 CH 2 COOCH 2 CH 3 , —NHOY′ where Y′ is hydrogen, methyl, iso-propyl or benzyl, —O—(N-succinimidyl), —O-cholest-5-en-β-yl, —OCH 2 —OC(O)C(CH 3 ) 3 , —O(CH 2 ) z NHC(O)W where z is 1 or 2 and W is selected from the group consisting of pyrid-3-yl, N-methylpyridyl, and N-methyl-1,4-dihydro-pyrid-3-yl, —NR″C(O)—R′ where R′ is aryl, heteroaryl or heterocyclic and R″ is hydrogen or —CH 2 C(O)OCH 2 CH 3 .
11. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound selected from the group consisting of:
N-(toluene-4-sulfonyl)sarcosyl-L-4-(N,N-dimethylcarbamyloxy)phenylalanine isopropyl ester
N-(toluene-4-sulfonyl)sarcosyl-L-4-(N,N-dimethylcarbamyloxy) phenylalanine tert-butyl ester
N-(toluene-4-sulfonyl)sarcosyl-L-4-(N,N-dimethylcarbamyloxy)phenylalanine
N-(toluene-4-sulfonyl)sarcosyl-L-4-(morpholin-4-ylcarbonyloxy)phenylalanine tert-butyl ester
N-(toluene-4-sulfonyl)sarcosyl-L-4-(4-methylpiperazin-1-ylcarbonyloxy)phenylalanine tert-butyl ester
N-(toluene-4-sulfonyl)-L-N-methylalanyl-L-4-(4-methylpiperazin-1-ylcarbonyloxy) phenylalanine tert-butyl ester
N-(toluene-4-sulfonyl)sarcosyl-L-4-(thiomorpholin-4-ylcarbonyloxy)phenylalanine tert-butyl ester
N-(toluene-4-sulfonyl)-L-N-methylalanyl-L-4-(4-methylpiperazin-1-ylcarbonyloxy) phenylalanine
N-(toluene-4-sulfonyl)sarcosyl-L-4-(1,1-dioxothiomorpholin-4-ylcarbonyloxy)phenylalanine tert-butyl ester
N-(toluene-4-sulfonyl)sarcosyl-L-4-(thiomorpholin-4-ylcarbonyloxy)phenylalanine
N-(toluene-4-sulfonyl)-L-N-methylalanyl-L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-butyl ester
N-(toluene-4-sulfonyl)sarcosyl-L-4-(1,1-dioxothiomorpholin-4-ylcarbonyloxy)phenylalanine
N-(toluene-4-sulfonyl)-L-N-methylalanyl-L-4-(N,N-dimethylcarbamyloxy)phenylalanine
N-(toluene-4-sulfonyl)-L-N-methyl-2-(tert-butyl)glycinyl-L-4-(4-methylpiperazin-1-ylcarbonyloxy) phenylalanine tert-butyl ester
N-(methanesulfonyl)-N-benzylglycinyl-L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-butyl ester
or pharmaceutically acceptable salts thereof as well as any of the ester compounds recited above wherein one ester is replaced with another ester selected from the group consisting of methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, sec-butyl ester, tert-butyl ester and neopentyl ester.